oasis trial
Semaglutide vs Compounding: Which Rules?
Semaglutide vs Compounding: Which Rules? In 2024, the FDA excluded semaglutide, tirzepatide and liraglutide from the 503B bulk list, effectively preventing compounding of these GLP-1 agents. Thus, clinicians must prescribe the approved products rather than rely on compounded alternatives. Medical Disclaimer: This article is for informational purposes only and does